Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

´ëÀå¾ÏÀÇ ´Ù¹ß¼º °£ÀüÀÌ¿¡ ´ëÇÑ °£µ¿¸Æ Ç×¾ÏÁ¦ÁÖ»ç¿ä¹ý Hepatic Intraarterial Chemotherapy in Unresectable Hepatic Metastases of Colorectal Cancer

´ëÇѾÏÇÐȸÁö 1997³â 29±Ç 2È£ p.227 ~ 234
¼Ò¼Ó »ó¼¼Á¤º¸
±èÁøõ/Jin Cheon Kim ÀÌÇÑÀÏ/À¯Ã¢½Ä/±èÈñ¿ø/±è»óÀ§/ÀÌÁ¤½Å/¹Ú°ÇÃá/Han Il Lee/Chang Sik Yu/Hee Won Chung/Sang Wee Kim/Jeong Sin Lee/Kun Choon Park

Abstract

¼­·Ð
´ëÀå¾ÏÀº ÃÖ±Ù ½Ä»ýÈ°ÀÇ º¯È­¿Í À¯Àü¼º¼ÒÀÎÀÇ ±Ô¸í ¹× ´ëÀå³»½Ã°æÀÇ º¸ÆÝÈ­µîÀ¸·Î Áõ°¡
Ãß¼¼¿¡ ÀÖ´Ù. ´ëÀå¾ÏÀÇ Ä¡·á´Â ¾à 75%¿¡¼­ ±ÙÄ¡Àû ÀýÁ¦¼úÀÌ ½ÃÇàµÇÁö¸¸ óÀ½ Áø´Ü½Ã ¾à 1
0¡­25%¿¡¼­ °£ÀüÀÌ°¡ µ¿½Ã¿¡ ¹ß°ßµÇ¸ç ¶ÇÇÑ ±ÙÄ¡¼ö¼úÈÄ ¾à ¹Ý¼ö¿¡¼­ °£¿¡ Àç¹ßµÇ¾î ÀÌ¿¡
´ëÇÑ µ¿¹Ý Ä¡·á¸¦ ¿äÇÏ°Ô µÈ´Ù. ´ëÀå¾ÏÀ¸·ÎºÎÅÍ ÀüÀÌµÈ °£¾ÏÀº ŸÀå±â·Î ÀüÀ̾øÀÌ °£¿¡¸¸
±¹ÇѵǴ °æ¿ì°¡ ¸¹À¸¸ç ±¹ÇѼºÀÎ °æ¿ì ¼ö¼úÀû ÀýÁ¦°¡ È¿°úÀûÀ¸·Î¼­ ¿ÏÀüÈ÷ Á¦°ÅµÈ °æ¿ì 5
³â»ýÁ¸À²ÀÌ 32¡­48%±îÁö º¸°íµÇ°í ÀÖ´Ù. ±×·¯³ª °£ÀüÀ̽à À§Ä¡, ´Ù¹ß¼º Á¤µµ ¹× Àü½Å»óÅ¿¡
µû¶ó ¿Ü°úÀû ÀýÁ¦ÀÇ ÀûÀÀÀÌ µÇ´Â °æ¿ì°¡ 8¡­25%¿¡ ºÒ°úÇÏ°í Á¤¸ÆÀ» ÅëÇÑ Àü½Å¼º Ç×¾ÏÁ¦Åõ
¿©³ª, ÀüÀ̾Ͽ¡ ´ëÇÑ Á÷Á¢ÀûÀÎ ³Ãµ¿Ä¡·á ȤÀº ¹æ»ç¼± µ¿À§¿ø¼ÒÄ¡·á µîÀ» ½ÃÇàÇÏÁö¸¸ Ä¡·á°á
°ú»ó ¹ÌÈíÇÏ´Ù
°£µ¿¸ÆÀ» ÅëÇÑ ±¹¼ÒÀû Ç×¾ÏÁ¦ Åõ¿©´Â 1983³â Cohenµî¿¡ ÀÇÇØ Ã³À½ ¹ßÇ¥µÈ ÀÌ·¡ Á¾¾ç¼¼Æ÷
°¡ Á¤»ó¼¼Æ÷¿Í ´Þ¸® µ¿¸ÆÇ÷·ÎºÎÅÍ ¿µ¾á°ø±ÞÀ» ¹Þ´Â´Ù´Â »ç½Ç°ú °æÁ¤¸Æ Åõ¿©º¸´Ù ¾à 15¹èÁ¤
µµ °£³» Ç÷Áß Ä¡·á¿ë·®À» ³ôÀÏ ¼ö ÀÖÀ¸¸ç Á¤¸ÆÇ÷º¸´Ù fluorodeoxyuridine(FUDR)¿¡ ´ëÇÑ Ä¡
·á¹ÝÀÀÀÌ ´õ ³ô´Ù´Â °á°ú·ÎºÎÅÍ ³ô°Ô´Â 83%±îÁö Ä¡·á ¹ÝÀÀÀÌ º¸°íµÇ°í ÀÖÁö¸¸ ºñ±³Àû ³ôÀº
°£µ¶¼ºÀÌ ¹®Á¦Á¡À¸·Î ÁöÀûµÇ°í ÀÖ´Ù.
ÀúÀÚµéÀº °£µ¶¼ºÀÇ ´ÜÁ¡À» º¸¿ÏÇÒ ¼ö ÀÖ´Â ¼ö¼ú¹æ½ÄÀ¸·Î °£µ¿¸Æ Ç÷·ù¸¦ À¯ÁöÇÒ ¼ö ÀÖ´Â
¼ú½ÄÀ» äÅÃÇÏ¿© Ç×¾ÏÁ¦ÀÇ °£³» °í³óµµ¸¦ À¯ÁöÇÒ ¼öÀÖ´Â Ç×¾ÏÁÖ»ç¿ä¹ýÀ» ½ÃÇàÇÏ¿´À¸¸ç ±×
Ä¡·áÈ¿°ú ¹× µ¶¼ºÀ» Àü½Å¼º Ç׾Ͽä¹ý°ú ºñ±³ÇÏ¿´´Ù.
#ÃÊ·Ï#
Purpose : Unresectable hepatic metastases of colorectal cancer does not seem to be
amenable to the various treatment modalities. We modified hepatic intraarterial
chemotherapy by different installation of port and regimen.
Materials and Methods : Between July 1989 to December 1995, 27 patients of
colorectal cancer with unresectable liver metastases were randomly allocated into either
hepatic intraarterial(HA, 11 patients) or systemic intravenous(IV, 16 patients)
chemotherapy after primary tumor resection. Chemo-port was installed with preservation
of hepatic arterial flow. One cycle of HA regimen included 5-fluorouracil(5-FU) and
mitomycin-C(MMC) with or without leucovorin(LV) for 14 days every month. The IV
regimen included 5-FU and LV for 5 days every month. Both HA and IV chemotherapy
were continued from 6 to 12 cycles.
Results : The response exceeding partial remission was experienced in six
patients(55%) among 11 patients in the HA group, while only two(13%) patients showed
response among sixteen patients in the IV group. One year survival was not different
between two groups. Although lethal toxicity was not found, patients showed marked
increase of the performance scale(ECOG) in both groups.
Conclusion : Although survival benefit was not prominent, higher response rate with
tolerable complication was found in the HA group. Prudent selection of effective drugs
and combination of systemic chemotherapy are needed to improve the survival with
minimal complication.

Å°¿öµå

Regional chemotherapy; Colorectal cancer; Hepatic metastasis;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS